

Certificate of Analysis

PI3 Kinase (p110 β /p85 α), active (Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-603, 14-603-K, 14-603M

Parent Lot # 1994929

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: Complex of *N*-terminal 6His-tagged recombinant full-length human p110 β and untagged, recombinant, full length, human p85 α . Co-expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 72.9% by SDS-PAGE and Coomassie blue staining. P110 β MW = 124kDa, p85 α MW = 83.7kDa.

Specific Activity (Parent lot# 1994929): 144U/mg, where one unit of PI3 Kinase (p110 β) activity is defined as 1nmol phosphatidylinositol 3,4,5-trisphosphate formed per minute at 22°C with a final ATP concentration of 100 μ M.

Formulation: 0.534mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.



Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.1–3.1ng of this enzyme phosphorylated 10 μ M phosphatidylinositol 4, 5-bisphosphate in the assay referenced on page two.

MS Tryptic Fingerprint: Confirmed identity as PI3 Kinase (p110 β) with the translated sequence listed on pages three and five.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μ g of active PI3 kinase (p110 β).

Certificate of Analysis

Eurofins PI3 Kinase Homogeneous Time-resolved Fluorescence (HTRF) Class I Reagent Kits

The following Eurofins kits are suitable for use with this enzyme:

Cat. No	Kit Description
33-016	PI3 Kinase 4-Step Assay Reagent 1-Plate Kit
33-017	PI3 Kinase 4-Step Assay Reagent 5-Plate Kit
33-036	PI3 Kinase 4-Step Assay Reagent Kit (10000 wells)
33-037	PI3 Kinase 4-Step Assay Reagent Kit (50000 wells)
33-040	PI3 Kinase 3-Step Assay Reagent Kit (384 wells)
33-041	PI3 Kinase 3-Step Assay Reagent Kit (1920 wells)
33-047	PI3 Kinase 3-Step Assay Reagent Kit (10000 wells)

Kits 33-016, 33-017, 33-036 and 33-037 provide reagents and assay details for the Eurofins standard 4-step HTRF assay. This assay format is suitable for the majority of small and medium throughput screening work. The 3-step HTRF assay (kits 33-040, 33-041, 33-047) was introduced to reduce the number of assay steps to aid high throughput screening. Items 33-040 and 33-041 are intended as introductory kits for 3-step procedure work up. Please contact us for any further information regarding different kit formats (discoveryservices@eurofins.com).

Certificate of Analysis

p110 β Sequence Information

<u>Protein</u>	Human p110 β
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M10 of the recombinant protein is equivalent to M1 of human p110 β
<u>Accession number</u>	GenBank NM_006219

Recombinant p110 β amino acid sequence:

```

1  MHHHHHHEFM CFSFIMPPAM ADILDIWAVD SQIASDGSIP VDFLLPTGIY IQLEVPREAT
61  ISYIKQMLWK QVHNYPMFNL LMDIDSYMFA CVNQTAVYEE LEDETRRLCD VRPFLPVLKL
121 VTRSCDPGEK LDSKIGVLIG KGLHEFDSLK DPEVNEFRRK MRKFSEEKIL SLVGLSWMDW
181 LKQTYPPEHE PSIPENLEDK LYGGKLIVAV HFENCQDVFS FQVSPNMNPI KVELAIQKR
241 LTIHGKEDV SPYDYVLQVS GRVEYVFGDH PLIQFYIRN CVMNRALPHF ILVECKIKK
301 MYEQEMIAIE AAINRNSSNL PLPLPPKTR IISHVWENNN PFQIVLVKGN KLNTEETVKV
361 HVRAGLFHGT ELLCKTIVSS EVSGKNDHIW NEPLEFDINI CDLPRMARLC FAVYAVLDKV
421 KTKKSTKTIN PSKYQIRKA GKVHYPVAWV NTMVDFDKGQ LRTGDIIILHS WSSFPDELEE
481 MLNPMGTVQT NPYTENATAL HVKFPENKKQ PYYYPPFDKI IEKAAEIASS DSANVSSRGG
541 KKFLPVLKEI LDRDPLSQLC ENEMDLIWTL RQDCREIFPQ SLPKLLLSIK WNKLEDVAQL
601 QALLQIWPKL PPRALELLD FNYPDQYVRE YAVGCLRQMS DEELSQYLLQ LVQVLKYEPF
661 LDCALSRFL ERALGNRRIG QFLFWHLRSE VHIPAVSVQF GVILEAYCRG SVGHMKVLSK
721 QVEALNKLKT LNSLIKLNVA KLNRAKGEA MHTCLKQSAY REALSDLQSP LNPCVILSEL
781 YVECKYMDS KMKPLWLVPN NKVFGEDSVG VIFKNGDDL RQDMLTLQMLR LMDLLWKEAG
841 LDLRMLPYGC LATGDRSGLI EVVSTSETIA DIQLNSSNVA AAAAFNKDAL LNWLKEYNSG
901 DDLDRAIIEF TSCAGYCVV SYVLGIGDRH SDNIMVKKTG QLFHIDFGHI LGNFKSKFGI
961 KRERVPFILT YDFIHVIQGG KTGNTKFKGR FRQCCEDAYL ILRRHGNLFI TLFALMLTAG
1021 LPELTSVKDI QYLKDSLALG KSEEEALKQF KQKFDEALRE SWTTKVNWMA HTVRKDYSR

```

Recombinant p110 β nucleotide sequence:

```

1  atgcatcatc accatcacca tgaattcatg tgcttcagtt tcataatgcc tcctgctatg
61  gcagacatcc ttgacatctg ggcggtggat tcacagatag catctgatgg ctccatacct
121 gtggatttcc tttgcccac tgggatttat atccagttgg aggtacctcg ggaagctacc
181 atttcttata ttaagcagat gttatggaag caagttcaca attaccaat gttcaacctc
241 cttatggata ttgactccta tatgtttgca tgtgtgaatc agactgctgt atataggagg
301 cttgaagatg aaacacgaag actctgtgat gtcagacctt ttcttcagtt ctcaaatta
361 gtgacaagaa atgttgacct aggggaaaaa ttagactcaa aaattggagt ccttatagga
421 aaaggtctgc atgaatttga ttccttgaag gatcctgaag taaatgaatt tcgaagaaaa
481 atgcgcaaat tcagcgagga aaaaatcctg tcacttgggg gattgtcttg gatggactgg
541 ctaaaacaaa catatccacc agagcatgaa ccatccatcc ctgaaaactt agaagataaa
601 ctttatgggg gaaagctcat cgtagctggt cattttgaaa actgccagga cgtgttttagc
661 tttcaagtgt ctcctaatat gaatcctatc aaagtaaatt aattggcaat ccaaaaacgt
721 ttgactattc atgggaagga agatgaagtt agcccctatg attatgtggt gcaagtcagc
781 gggagagtag aatatgtttt tgggtgatcat ccactaattc agttccagta tatccggaac
841 tgtgtgatga acagagccct gccccatttt atacttgggg aatgctgcaa gatcaagaaa
901 atgtatgaac aagaaatgat tgccatagag gctgccataa atcgaaattc atctaattctt
961 cctcttccat taccacaaa gaaaacacga attatttctc atgtttggga aaataacaac
1021 cttttcaaaa ttgtcttggg taagggaaat aaacttaaca cagaggaaac tgtaaaagtt
1081 catgtcaggg ctggtctttt tcatggtact gagctcctgt gtaaaacat cgtaagctca
1141 gaggtatcag ggaaaaatga tcatatttgg aatgaaccac tggaaatttga tattaatatt
1201 tgtgacttac caagaatggc tcgattatgt tttgctggtt atgcagtttt ggataaagta
1261 aaaacgaaga aatcaacgaa aactattaat ccctctaaat atcagacctt caggaaagct
1321 ggaaaagtgc attatcctgt agcgtgggta aatacagatg tttttgactt taaaggacaa

```

Certificate of Analysis

```
1381 ttgagaactg gagacataat attacacagc tggctcttcat ttcctgatga actcgaagaa
1441 atgttgaatc caatgggaac tgttcaaac aatccatata ctgaaaatgc aacagctttg
1501 catgttaaat ttccagagaa taaaaaaca cttattatt accctccctt cgataagatt
1561 attgaaaagg cagctgagat tgcaagcagt gatagtgcata atgtgtcaag tcgaggtgga
1621 aaaaagtttc ttcctgtatt gaaagaaatc ttggacaggg atcccttgtc tcaactgtgt
1681 gaaaatgaaa tggatcttat ttggactttg cgacaagact gccgagagat tttcccacaa
1741 tcaactgcaa aattactgct gtcaatcaag tggaaataaac ttgaggatgt tgctcagctt
1801 caggcgtgc ttcagatttg gcctaaactg ccccccggg aggccctaga gcttctggat
1861 ttcaactatc cagaccagta cgttcgagaa tatgctgtag gctgcctgcg acagatgagt
1921 gatgaagaac tttctcaata tcttttaca ctggtgcaag tgttaaaata tgagcctttt
1981 cttgattgtg cctctcttag attcctatta gaaagagcac ttggtaatcg gaggataggg
2041 cagtttctat tttggcatct tagtcagaa gtgcacattc ctgctgtctc agtacaattt
2101 ggtgcatcc ttgaagcata ctgccgggga agtgtggggc acatgaaagt gctttctaag
2161 caggttgaag cactcaataa gttaaaaact ttaaataagt taatcaaact gaatgccgtg
2221 aagttaaaca gagccaaagg gaaggaggcc atgcatacct gtttaaaaca gagtgcctac
2281 cgggaagccc tctctgacct gcagtcaccc ctgaacccat gtgttatcct ctcagaactc
2341 tatgttgaaa agtgcaaata catggattcc aaaatgaagc ctttgtggct ggtatacaat
2401 aacaaggatc ttggtgagga ttcagttgga gtgattttta aaaatggtga tgatttacga
2461 caggatatgt tgacactcca aatggtgagc ttgatggatt tactctggaa agaagctggg
2521 ttgatcttc ggatgttgcc ttatggctgt ttagcaacag gagatcgctc tggcctcatt
2581 gaagtgtgta gcacctctga aacaattgct gacattcagc tgaacagtag caatgtggct
2641 gctgcagcag cttcaacaa agatgccctt ctgaaactggc ttaaagaata caactctggg
2701 gatgacctgg accgagccat tgaggaattt aactgtcct gtgctggcta ctgtgtagct
2761 tcttatgtcc ttgggattgg tgacagacat agtgacaaca tcatggtcaa aaaaactggc
2821 cagctcttcc acattgactt tggacatatt cttggaaatt tcaaacttaa gtttggcatt
2881 aaaagggagc gagtgccttt tattcttacc tatgatttca tccatgtcat tcaacaagga
2941 aaaacaggaa atacagaaaa gtttggccgg ttccgccagt gttgtgagga tgcatatctg
3001 attttacgac ggcatgggaa tctcttcac actctctttg cgctgatgtt gactgcaggg
3061 cttctgaac tcacatcagt caaagatata cagtatctta aggactctct tgcattaggg
3121 aagagtgaag aagaagcact caaacagttt aagcaaaaat ttgatgaggc gctcagggaa
3181 agctggacta ctaaagtga ctggatggcc cacacagttc ggaaagacta cagatcttaa
```

Certificate of Analysis

P85α Sequence Information

<u>Protein</u>	Human p85α
<u>Tags</u>	Untagged
<u>Native sequence</u>	M1 of the recombinant protein is equivalent to M1 of human p85α
<u>Accession number</u>	GenBank XM_043865

Recombinant p85α amino acid sequence:

```

1 MSAEGYQYRA LYDYKKEREE DIDLHLGDIL TVNKGSLVAL GFSDGQEARP EEIGWLNQYN
61 ETTGERGDFP GTYVEYIGRK KISPPTPKPR PPRPLPVAPG SSKTEADVEQ QALTLPLDLAE
121 QFAPPDIAPP LLIKLVFAIE KKGLECESTLY RTQSSSNLAE LRQLLDCDTP SVDLEMIDVH
181 VLADAFKRYL LDLPNVPIPA AVYSEMISLA PEVQSSEFYI QLLKKLIRSP SIPHQYWLTL
241 QYLLKHFFKL SQTSSKNLLN ARVLSEIFSP MLFRFSAASS DNTENLIKVI EILISTEWNE
301 RQPAPALPPK PPKPTTVANN GMNNSMLQD AEWYWGDISR EEVNEKLRDT ADGTFLVRDA
361 STKMHG DYTL TLRKGGNNKL IKIFHRDGKY GFSDDLTFSS VVELINHYRN ESQAQYNPKL
421 DVKLLYPVSK YQQDQVVKED NIEAVGKLLH EYNTQFQEK S REYDRLYEY TRTSQEIQMK
481 RTAIEAFNET IKIFEEQCQT QERYSKEYIE KFKREGNEKE IQRIMHNYDK LKSRISEIID
541 SRRRLEEDLK KQAAEYREID KRMNSIKPDL IQLRKTRDQY LMWLTQKGVR QKKLNEWLGN
601 ENTEDQYSLV EDEDLPHHD EKTWNVGS SN RNKAENLLRG KRDGTFLVRE SSKQGCYACS
661 VVVDGEVKHC VINKTATGYG FAEPYNLYSS LKELVLHYQH TSLVQHNSL NVTLAYPVYA
721 QRRR
  
```

Recombinant p85α nucleotide sequence:

```

1 atgagtgctg aggggtacca gtacagagcg ctgtatgatt ataaaaagga aagagaagaa
61 gatattgact tgcacttggg tgacatatg actgtgaata aagggtcctt agtagctctt
121 ggattcagtg atggacagga agccaggcct gaagaaattg gctggttaaa tggctataat
181 gaaaccacag gggaaagggg ggactttccg ggaacttacg tagaatatat tggaaagaaa
241 aaaatctcgc ctcccacacc aaagccccgg ccacctcggc ctcttcctgt tgcaccaggt
301 tcttcgaaaa ctgaagcaga tgttgaacaa caagctttga ctctcccgga tcttgcagag
361 cagtttgccc ctctgacat tgccccgctt cttcttatca agctcgtgga agccattgaa
421 aagaaaggtc tggaatgttc aactctatac agaacacaga gctccagcaa cctggcagaa
481 ttacgacagc ttcttgattg tgatacacc tccgtggact tggaaatgat c gatgtgcac
541 gttttggctg acgctttcaa acgctatctc ctggacttac caaatcctgt cattccagca
601 gccgtttaca gtgaaatgat ttctttagct ccagaagtac aaagctccga agaatatatt
661 cagctattga agaagcttat taggtcgcct agcatacctc atcagtattg gcttacgctt
721 cagtatgtgt taaaacattt cttcaagctc tctcaaacct ccagcaaaaa tctgttgaat
781 gcaagagtac tctctgaaat tttcagcctt atgcttttca gattctcagc agccagctct
841 gataatactg aaaacctcat aaaagtata gaaattttaa tctcaactga atggaatgaa
901 cgacagcctg caccagcact gcctcctaaa ccaccaaac ctactactgt agccaacaac
961 ggtatgaata acaatatgtc cttacaagat gctgaatggt actggggaga tatctcgagg
1021 gaagaagtga atgaaaaact tcgagataca gcagacggga cttttttggt acgagatgcg
1081 tctactaaaa tgcattggtga ttatactctt aactaagga aagggggaaa taacaaatta
1141 atcaaaaat ttcattcgaga tgggaaatat ggcttctctg acccattaac cttcagttct
1201 gtggttgaat taataaacca ctaccggaat gaatctctag ctcagtataa tcccaaattg
1261 gatgtgaaat tactttatcc agtatccaaa taccaacagg atcaagttgt caaagaagat
1321 aatattgaag ctgtagggaa aaaattacat gaatataaca ctcagtttca agaaaaagt
1381 cgagaatatg atagattata tgaagaatat accgcacat cccaggaaat ccaaatgaaa
1441 aggacagcta ttgaagcatt taatgaaacc ataaaaatat ttgaagaaca gtgccagacc
1501 caagagcggg acagcaaaga atacatagaa aagtttaaac gtgaaggcaa tgagaaagaa
1561 atacaaagga ttatgcataa ttatgataag ttgaagtctc gaatcagtga aattattgac
1621 agtagaagaa gattggaaga agacttgaag aagcaggcag ctgagtatcg agaaattgac
  
```

Certificate of Analysis

```
1681 aaacgtatga acagcattaa accagacctt atccagctga gaaagacgag agaccaatac
1741 ttgatgtggt tgactcaaaa aggtgttcgg caaaagaagt tgaacgagtg gttgggcaat
1801 gaaaacactg aagaccaata ttcactgggt gaagatgatg aagatttgcc ccatcatgat
1861 gagaagacat ggaatgttgg aagcagcaac cgaaacaaag ctgaaaacct gttgagaggg
1921 aagcgagatg gcacttttct tgtccgggag agcagtaaag agggctgcta tgcctgctct
1981 gtagtgggtg acggcgaagt aaagcattgt gtcataaaca aaacagcaac tggctatggc
2041 tttgccgagc cctataactt gtacagctct ctgaaagaac tgggtgctaca ttaccaacac
2101 acctcccttg tgcagcacia cgactccctc aatgtcacac tagcctaccc agtatatgca
2161 cagcagaggc gatga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.